Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Humana reports first quarter 2020 results

A quarter marked by mobilisation, unity and heroic effortsHumana’s main focus during the first quarter, and mainly during its second half, was, like the rest of our society, focused on preparing for and managing the new coronavirus. Humana serves 9,000 customers and clients, and all operations must preventing spread and handling any cases of covid-19. Financially, the development was good. Humana’s revenue increased by 13 percent, including 4 percent organically, and the operating profit increased despite the negative effects connected to the pandemic in the second half of the quarter.

Outotec’s interim report January-March 2020

OUTOTEC OYJ INTERIM REPORT MAY 7, 2020 AT 9:00 AM   Outotec’s interim report January-March 2020  Growth in sales and adjusted EBIT, uncertain operating environment affected order intake “COVID-19 caused rapid uncertainty impacting the global operating environment and prompting travel restrictions, sourcing challenges and limiting access to customer sites.   Order intake decreased by 28% compared to the comparison period because customers started to slow down decision-making relating to large projects. In the Minerals Processing segment, smaller equipment orders continued to be

BioGaia Interim Management Statement 1 January – 31 March 2020

Increased product sales resulted in a good start of the year Net sales amounted to SEK 182.8 million (171.3), an increase of 7% (excluding foreign exchange effects, 4%). Product sales, net sales excluding royalty revenues, amounted to SEK 177.0 million (164.5), an increase of 8% (excluding foreign exchange effects, 5%). Net sales in the Paediatrics segment reached SEK 142.5 million (133.6), an increase of 7%. Product sales within Paediatrics amounted to SEK 139.3 million (128.1), an increase of 9%. Net sales in the Adult Health segment amounted to SEK 40.2 million (37.6), an

Tradedoubler Interim Report January - March 2020

The first quarter January – March 2020 · Net sales amounted to SEK 305 M (306) a decrease of -1% or -3% adjusted for changes in exchange rates compared to the same period last year. · Gross profit adjusted for change related items was SEK 63 M (66), a decrease of -4% or -6% adjusted for changes in exchange rates. Gross margin adjusted for change related items was 20.7% (21.5). · Operating costs excluding depreciation and change related items were SEK 49M (53), a decrease of -7%. · EBITDA amounted to SEK 14 M (13). Adjusted for change related items, EBITDA was SEK 14 M (13).

InDex Pharmaceuticals Holding AB (publ) interim report January – March 2020

FDA and EMA endorse the advancement of cobitolimod into phase III studies“The positive responses from the regulators is an important external validation of our study results and cobitolimod’s potential,” says Peter Zerhouni, CEO of InDex Pharmaceuticals. Period January – March 2020 · Net sales amounted to SEK 0.0 (0.0) million · Operating loss amounted to SEK –24.0 (–17.2) million · Result after tax amounted to SEK –24.0 (–17.2) million, corresponding to SEK –0.27 per share (–0.25) before and after dilution · Cash flow from operating activities amounted to SEK –21.9 (–18.4)

Interim report first quarter 2020

Irisity AB (publ) delivers strong first quarter with growth and increased profitability.CEO comments on first quarter: Net sales during the period amounted to MSEK 9.8 (8.4), the work performed for own account to MSEK 3.1 (4.5). EBITDA amounted to MSEK -0.8 (-1.5) and the profit after tax was MSEK -4.2 (-4.5). Gross margin was 64.3 percent (60.3). Cash position MSEK 34.6. Despite the general uncertainty and impact from measures put in place by authorities around the world to reduce the spread of COVID-19, we deliver a strong quarter. In terms of net sales, the quarter is a new record.

NCC to construct Manglerud Swim Center in Oslo

NCC Building has commenced the construction of Manglerud Swim and Activity Center on behalf of Undervisningsbygg KF. On May 6 this year, the Oslo City Council approved the commencement of the construction. The order value is approximately NOK 385 million. Illustration: Asplan Viak   “We are looking forward to commencing construction of this facility, which in addition to three swimming pools will provide space for a number of leisure activities. Together with the developer and its advisers, we have developed a project that I am certain will be greatly appreciated by the residents

Read original

Award of Phase 1 SURF Contract to Subsea 7

7 May 2020   Independent Oil and Gas plc  Award of Phase 1 SURF Contract to Subsea 7  Independent Oil and Gas plc ("IOG" or "the Company"), (AIM: IOG.L), the development and production company focused on becoming a substantial UK gas producer, as operator of its joint venture with CalEnergy Resources (UK) Ltd, is pleased to announce that it has awarded a sizeable Engineering, Procurement, Construction and Installation (EPCI) contract to Subsea 7 S.A.. The contract will cover the Subsea, Umbilicals, Risers and Flowlines (SURF) work on Phase 1 of its Core Project in the UK

Finnair Traffic Performance in April 2020

Finnair Plc                Investor News        7 May 2020 at 9:00 a.m. EEST  Finnair’s significant capacity reductions due to the coronavirus impact were clearly visible in all traffic figures In April, Finnair carried 16,100 passengers which is 98.7% less than in the corresponding period of 2019. The overall capacity measured in Available Seat Kilometres (ASK) decreased in April by 97.0%. Finnair's traffic measured in Revenue Passenger Kilometres (RPKs) decreased by 99.1%. The Passenger Load Factor (PLF) decreased year-on-year by 57.5% points to 23.9%. All traffic figures were

Interim report January-March 2020

Growth of income from property management During the first quarter of the year, 29 basic and total upgrades of apartments were completed and in 107 apartments upgrades are ongoing. During the quarter, we have prepared for taking possession of the property portfolio in the Rotebro and Rotsunda areas of the municipality of Sollentuna. During the period, rental income increased by 5% and management income per share by 59%, partly explained by an improved net operating income and partly by the quarter not being burdened with costs related to the IPO. - The long-term impact of the Corona

Polygiene AB (publ.) Interim Report 1 January–31 March 2020

A quarter impacted by Covid-19 and new opportunitiesQ1 in brief · Positive growth due to increased net sales by 4.4 % during the quarter compared to the same period last year and amounted to MSEK 17.4 (16.7). · The operating profit/loss before tax for the period is improved compared to the same period last year and amounted to MSEK 0.2 (-1.1). · The gross margin has decreased at 67.2 (67.6) %. · Cash flow of the first quarter was positive and amounted to MSEK 2.2 (6.4). · ViralOff has launched as a new brand. Events during Q1 2020 (Jan-Mar) · New CFO, Nina Forsvall,

Pernille Erenbjerg joins the board of GlobalConnect/IP-Only

Pernille Erenbjerg, former CEO of TDC Group, now joins the board of GlobalConnect/IP-Only. Together with the rest of the board and group leadership, she will realize the ambition to create the leading digital infrastructure provider in Northern Europe.Pernille Erenbjerg is part of the board at Nordea, Genmab and the telecom company Milicom and adjunct professor at Copenhagen Business School. She has held multiple leadership positions during 15 years at TDC Group. “I am incredibly pleased that Pernille now joins the board. Our mission to become Northern Europe’s leading supplier of

ContextVision Annual General Meeting

On the 6th of May 2020, ContextVision held its ordinary Shareholders' Annual General Meeting in Stockholm. · The annual financial report regarding 2019 was presented and approved by the AGM. · Disposition of financial results according to the proposal of the Board of Directors was approved. · The Managing Director and the Board of Directors were discharged from liability. · The proposed guidelines for remuneration to the Board of Directors and senior executives was approved. · Board compensation was decided according to the following: · The chairman of the board will

Verdane partners with e-health company Evondos to improve home care of elderly in Nordics

SALO/OSLO – Verdane, the specialist Northern European growth equity investor, has announced its investment in Evondos, the Finland-based Nordic leader in automated medicine dispensing services for elderly home care clients. Patient safety and the well-documented reliability of Evondos’ automated medicine dispensing service for independent living and improved medical adherence have made Evondos the partner of choice for over 200 regions and municipalities. Its growth partnership with Verdane aims to develop Evondos’ service offering and extend the company’s market leadership into Northern

Recipharm AB publishes its interim report January-March 2020

January – March 2020 · Consort Medical Plc consolidated from February 2020 · Continued solid organic growth · Net sales amounted to SEK 2,593 million (1,812), an increase of 43% · EBITDA increased by 48% and amounted to SEK 431 million (291) corresponding to an EBITDA margin of 16.6% (16.1) · EBITA increased by 56% and amounted to SEK 267 million (171) corresponding to an EBITA margin of 10.3% (9.4) · Operating profit (EBIT) amounted to SEK -29 million (111), adjusted Operating profit amounted to SEK 164 (111). · Profit after tax amounted to SEK -230 million (79)

Nordic Nanovector ASA: Increase of share capital

Oslo, Norway, 7 May 2020   Three of the board members of Nordic Nanovector ASA (the "Company"), Gisela Schwab, Joanna Horobin and Jean-Pierre Bizzari have resolved to settle a total number of 9,761 RSUs. The RSU’s were issued to them in May 2019 after they had elected to receive all or part of their remuneration for the period from the annual general meeting in 2019 to the annual general meeting in 2020 in RSUs. In addition, board member Hilde Steineger has resolved to settle a total number of 8,818 RSUs previously issued as remuneration under the RSU-program. Each RSU gives the right to

INTERIM REPORT 1 JANUARY – 31 MARCH 2020

Q-linea signs global partnership with Thermo Fisher Scientific for commercialization of ASTarFirst quarter, 1 January –31 March 2020 · Net sales amounted to SEK 0.2 million (0.4). · The operating result totalled SEK -55.9 million (-36.7). · The result for the period amounted to SEK -56.0 million (-36.3). · Earnings per share before and after dilution amounted to SEK -2.44 (-1.59). · Cash flow from operating activities totalled SEK -59.1 million (-41.0). · At 31 March 2020, cash and cash equivalents amounted to SEK 28.3 million (26.0). Short-term investments in fixed-

SpareBank 1 SR-Bank ASA (SRBANK): Good underlying operations and strengthened solidity, but results marked by impairments and reduced financial income

SpareBank 1 SR-Bank posted a pre-tax profit of NOK 247 million at the end of the first quarter, compared with NOK 1,323 million for the same period last year. The results were marked by impairments and weak financial income. These resulted from the changed market conditions for offshore-related operations, a significantly poorer level of activity for companies in general, and weak financial markets due to the Covid-19 situation.  The return on equity after tax was NOK 3.4%, compared with 21.2% in the same quarter last year. The Common Equity Tier 1 capital ratio as at 31 March 2020 was

Gasum Group Q1 2020 - Gas plays a strong role in energy supply

Key financial indicators January 1 to March 31 2020*·The Group’s operating profit totaled €12.3 million, down 29.7% year on year (March 31, 2019: €17.5 million). · Operating profit margin in Q1 was 6.9%, up 1.4% compared with the reference year’s continuing operations (March 31, 2019: 5.5%). · Balance sheet total came to €1,133 million (March 31, 2019: €1,139 million) · The Group’s solvency remained strong in the reporting period, with the equity ratio being 44.1% (March 31, 2019: 40.7%). \* Including comparable figures for continuing operations\  Gasum Group CEO

Photocure ASA: Results for the first quarter of 2020

Oslo, Norway, 7 May 2020: Photocure ASA (OSE:PHO) announced the first quarter 2020 results in the trading update 27 April 2020, stating a revenue growth of 33% for the U.S. market in the first quarter of 2020, contributing to Hexvix[®]/Cysview[®] revenues of NOK 54.4 million (Q1 2019: NOK 51.2 million) and an EBITDA of NOK -4.8 million (NOK -1.5 million). The company has agreed terms with Ipsen Pharma SAS (Ipsen) for the return of Hexvix sales, marketing and distribution rights from the fourth quarter of 2020 and sees significant growth opportunities in Europe. The agreement is expected to be

HKScan’s annual comparable EBIT turned positive

HKScan Corporation      Interim Report   7 May 2020 at 8:00 a.m. EETHKScan’s annual comparable EBIT turned positive  January–March 2020 · HKScan’s net sales increased by 6.8 per cent and were EUR 428.9 (401.8) million. · EBIT improved by EUR 10.8 million to EUR -3.9 (-14.7) million. · Comparable EBIT improved by EUR 6.2 million to EUR -3.9 (-10.1) million. · On an annual level (rolling 12 months), comparable EBIT turned positive and wasEUR 3.9 million. · Commercial successes and growth of sales volumes as well as operational efficiency measures were the most

Sedana Medical AB (publ), interim report Q1, 2020

Hard work to meet the intensive care needs during COVID-19Financial Summary January-March · Net sales during the quarter amounted to KSEK 33 832 (17 814) corresponding to an increase of 90% compared with the same period in 2019.  · Earnings before interest, taxes, depreciation and amortization (EBITDA) amounted to KSEK 1 204 (-2 641). This corresponds to an EBITDA margin of 3,6% (-14,8%).  · Earnings before interest and taxes (EBIT) amounted to KSEK 82 (-3 660) which corresponds to an EBIT margin of 0,2%(-20,5%).  · Earnings per share before dilution was SEK 0,07 and

There are no items matching the current filter
There are no more items matching the current filter
Back to top